A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Trial ID #	NCT02889900; CONCERTO
Phase	II
Drug Class	DNA Damage Repair Pathway Inhibitors: PARP
Drug Name	Olaparib
Alternate Drug Names	AZD2281, Lynparza
Drugs in Trial	Cediranib, Olaparib
Eligible Participant	Platinum resistant ovarian cancer with at least 3 prior therapies
Patients Enrolled	60 non-gBRCA MUT or unk; median 4 prior therapies (3-10)
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DCR, DoR, PFS, OS, evaluated per RECIST
Efficacy	ORR: 15.6% (1CR, 8PR, n=59) DCR: 23.7% DoR: 8.3 months PFS: 5.1 months OS: 13.2 months
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE: overall (73%)
Conclusion	Olaparib+cediranib has manageable toxicity and shows evidence of anti-tumor activity in heavily pretreated platinum resistant non-gBRCA MUT patients
Reference	Lee J-M et al. Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial. Clin Cancer Res (2022) 28(19):4186-4193 https://pubmed.ncbi.nlm.nih.gov/35917514/